Inhibitors of LSD1 as a potential therapy for acute myeloid leukemia

  title={Inhibitors of LSD1 as a potential therapy for acute myeloid leukemia},
  author={Amanda Przespolewski and E. Wang},
  journal={Expert Opinion on Investigational Drugs},
  pages={771 - 780}
  • Amanda Przespolewski, E. Wang
  • Published 2016
  • Biology, Medicine
  • Expert Opinion on Investigational Drugs
  • ABSTRACT Introduction: Epigenetic dysregulation plays a critical role in the pathogenesis of acute myeloid leukemia (AML). Alterations in histone methylation lead to aberrant silencing of expression of multiple genes involved in tumor suppression and cell cycling, resulting in myeloid maturation arrest and proliferation of early myeloid progenitors. One promising approach targeting chromatin regulatory proteins is inhibition of lysine specific demethylase-1 (LSD1), an enzyme responsible for… CONTINUE READING
    17 Citations
    Biology of DNMT3 and LSD1 inhibition in acute myeloid leukaemia (AML)
    • PDF
    Rewiring the Epigenetic Networks in MLL-Rearranged Leukemias: Epigenetic Dysregulation and Pharmacological Interventions
    • 16
    • PDF
    Advances toward LSD1 inhibitors for cancer therapy.
    • 46
    • PDF
    The new perspectives of targeted therapy in acute myeloid leukemia.
    • A. Walasek
    • Medicine
    • Advances in clinical and experimental medicine : official organ Wroclaw Medical University
    • 2019
    • 9
    • PDF
    LSD1/KDM1A inhibitors in clinical trials: advances and prospects
    • 35
    Lung Cancer Therapy Targeting Histone Methylation: Opportunities and Challenges
    • 12
    Therapies Targeting Leukemic Stem Cells


    LSD1 inhibition: a therapeutic strategy in cancer?
    • 94
    RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
    • 1,445
    Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers
    • 354